These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8424585)

  • 21. Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg.
    Bergan JJ
    Angiology; 2005; 56 Suppl 1():S21-4. PubMed ID: 16193222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.
    Cesarone MR; Belcaro G; Pellegrini L; Ledda A; Vinciguerra G; Ricci A; Di Renzo A; Ruffini I; Gizzi G; Ippolito E; Fano F; Dugall M; Acerbi G; Cornelli U; Hosoi M; Cacchio M
    Angiology; 2006; 57(2):131-8. PubMed ID: 16518519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon.
    Frick RW
    Angiology; 2000 Mar; 51(3):197-205. PubMed ID: 10744007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
    Struckmann JR; Nicolaides AN
    Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency.
    Katsenis K
    Curr Vasc Pharmacol; 2005 Jan; 3(1):1-9. PubMed ID: 15641940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy.
    Ting AC; Cheng SW; Wu LL; Cheung GC
    Vasc Surg; 2001; 35(6):443-7. PubMed ID: 16222383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg.
    Le Dévéhat C; Khodabandehlou T; Vimeux M; Kempf C
    Int J Microcirc Clin Exp; 1997; 17 Suppl 1():27-33. PubMed ID: 9477042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg.
    Bergan JJ; Schmid-Schönbein GW; Takase S
    Angiology; 2001 Aug; 52 Suppl 1():S43-7. PubMed ID: 11510596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic Diosmin in the therapy of venous diseases.
    Signorelli S; Ferrara M; Tornetta D; Interlandi S; Amico-Roxas MT; Monaco S; Andreozzi GM
    Panminerva Med; 1987; 29(2):165-7. PubMed ID: 3627817
    [No Abstract]   [Full Text] [Related]  

  • 30. Capillary filtration in idiopathic cyclic edema--effects of Daflon 500 mg.
    Behar A; Lagrue G; Cohen-Boulakia F; Baillet J
    Nuklearmedizin; 1988 Jun; 27(3):105-7. PubMed ID: 3043383
    [No Abstract]   [Full Text] [Related]  

  • 31. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency.
    Allegra C; Bartolo M; Carioti B; Cassiani D
    Int J Microcirc Clin Exp; 1995; 15 Suppl 1():50-4. PubMed ID: 8748890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute effects of hydroxyethylrutosides on capillary filtration in normal volunteers, patients with venous hypertension and in patients with diabetic microangiopathy (a dose comparison study).
    Cesarone MR; Laurora G; Ricci A; Belcaro G; Pomante P; Candiani C; Leon M; Nicolaides AN
    Vasa; 1992; 21(1):76-80. PubMed ID: 1580094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
    Duchene Marullaz P; Amiel M; Barbe R
    Int Angiol; 1988; 7(2 Suppl):25-32. PubMed ID: 3053940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. At the Crossroads of Venous Insufficiency and Hemorrhoidal Disease: Daflon 500 mg. Proceedings of a symposium. Vienna, Austria, January 31, 1992.
    Angiology; 1994 Jun; 45(6 Pt 2):493-584. PubMed ID: 7911285
    [No Abstract]   [Full Text] [Related]  

  • 35. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study.
    Belcaro G; Rosaria Cesarone M; Ledda A; Cacchio M; Ruffini I; Ricci A; Ippolito E; Di Renzo A; Dugall M; Corsi M; Marino Santarelli AR; Grossi MG
    Angiology; 2008; 59 Suppl 1():7S-13S. PubMed ID: 18287162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study.
    Shoab SS; Scurr JH; Coleridge-Smith PD
    Eur J Vasc Endovasc Surg; 1999 Oct; 18(4):334-8. PubMed ID: 10550269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema.
    Ramelet AA
    Angiology; 2000 Jan; 51(1):19-23. PubMed ID: 10667639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Edema as a measure for severity of chronic venous insufficiency and efficacy of its treatment].
    Sapelkin SV
    Angiol Sosud Khir; 2008; 14(3):79-81. PubMed ID: 19791434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacology of the drugs prescribed for chronic venous diseases].
    Talibov OB
    Khirurgiia (Mosk); 2019; (2):106-109. PubMed ID: 30855600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vital capillaroscopy on microcirculation: pharmacodynamic activity of Daflon 500 mg in venous insufficiency.
    Balas P; Pagratis N
    Int Angiol; 1989; 8(4 Suppl):51-2. PubMed ID: 2632650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.